Differential Expression of Fourteen Proteins between Uveal Melanoma from Patients Who Subsequently Developed Distant Metastases versus Those Who Did Not

Abstract Purpose To report the prevalence of uveal melanoma in a Hospital database in Brazil over the period of 16 years (2000 to 2016). Design Descriptive epidemiological study evaluating the Brazilian Hospital Based Cancer Registries. Participants/methods Uveal melanomas were identified based on ICD-O-3 codes C69.3 [choroid], C69.4 [ciliary body and iris], and C69.2 [retina]) derived from the Integrator Registry database. Kolmogorov–Smirnov Test was used for evaluation of normality of data, t-test and Chi square were used for categorical and continuous variables respectively using SPSS Software. Main outcome measures Age, sex, education, regional distribution, clinical staging at the diagnosis, time from diagnosis to treatment (≤ 60 days versus > 60 days) and first-course therapy (surgery, chemotherapy, radiotherapy or a combination of such). Results There were 2166 cases of uveal melanoma representing 5.4% of all cases of melanoma. Histological confirmation of uveal melanoma was available in all cases. Higher prevalence of 1139 cases (52.6%) in women than 1027 cases (47.4%) in men was observed. Age distribution revealed 1411 cases (65.1%) in the group between 41 and 69 years old. A total of 429 (19.8%) patients were classified as initial disease and 334 (15.4%) as advanced (regional or distant metastases). Staging as initial disease was more frequent (113–24.8%) in patients with > 8 school years than in patients with < 8 school years (179–17.6%) reflecting disparities in healthcare access between those two populations. No difference was noticed in terms of diagnosis, staging and treatment after the Brazilian “60 days law” (Federal Law 12.732/12) came into effect in 2013 regulating the maximum period that a patient with cancer has to wait until start the treatment. Conclusion Epidemiological data is critical for planning early treatment strategies and allocating medical resources. This study intended to understand the characteristics of uveal melanoma in Brazil.

Download Full-text

Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma

Melanoma Research ◽

10.1097/00008390-200512000-00003 ◽

2005 ◽

Vol 15 (6) ◽

pp. 495-502 ◽

Cited By ~ 4

Author(s):

Jose L. Ordonez ◽

Luminita Paraoan ◽

Paul Hiscott ◽

Donna Gray ◽

Marta Garc??a-Fi??ana ◽

...

Keyword(s):

Differential Expression ◽

Uveal Melanoma ◽

Matricellular Proteins

Download Full-text

A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e22059 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e22059-e22059

Author(s):

Takami Sato ◽

Marlana M. Orloff ◽

Matias Emanuel Valsecchi ◽

Ayako Shimada ◽

Inna Chervoneva ◽

...

Keyword(s):

Valproic Acid ◽

High Risk ◽

Uveal Melanoma ◽

Adjuvant Treatment ◽

Survival Rates ◽

Distant Metastases ◽

Toxicity Assessment ◽

Primary Tumors ◽

Systemic Metastasis ◽

Melanoma Patients

e22059 Background: Uveal melanoma is the most common primary intraocular cancer in adults. Despite successful treatment of primary tumors, up to 50% of patients later die of distant metastases. Currently, no effective adjuvant treatment is available. Presence of both monosomy 3 and 8q amplification (M3 + 8q amp) or DecisionDx-UM Class 2 in the primary uveal melanoma characterizes a group of patients with high metastatic death rates with reported 2-year survival rates ranging from 50% to 78%. This study aims to decrease or delay the death from metastatic uveal melanoma. Methods: Uveal melanoma patients with high risk for systemic metastasis defined as any of the following were eligible: A) M3 + 8q amp; B) Class 2. Patients must show no evidence of systemic metastasis and they need to be enrolled within 6 months of initial treatment of primary uveal melanoma. Patients were randomized to receive either sunitinib 25 mg daily or valproic acid (VPA) 750 mg daily as adjuvant treatment for 6 consecutive months. Improvement of 2-year overall survival (OS) rate from historical reference (70%) to 85% was the primary endpoint. The secondary endpoints included 1) systemic relapse-free survival (RFS) rate at 18 months, 2) ability to complete adjuvant treatment and, 3) toxicity assessment. The study was not powered to compare the efficacy between each arm. Results: A total of 90 patients were enrolled in this study. Two patients were excluded from the study including one in the sunitinib arm (did not start treatment after randomization) and one in the VPA arm (refused to stop VPA at 6 months). Nine of 45 patients in the sunitinib arm and 4 of 43 patients in the VPA arm could not complete the 6-month treatment due to toxicity (sunitinib n = 6, VPA n = 2) or systemic progression (sunitinib n = 3, VPA n = 2). The rest of patients completed the 6-month course of study treatments and all patients were followed at least for 2 years. With a median follow-up of 40.2 months, the 2-year OS rates of the sunitinib and VPA group were 95.6% (90% CI 86.5-98.6) and 90.7% (90% CI 80.1 - 95.8), respectively. The 18-month RFS rates of the sunitinib and VPA group were 75.6% (90% CI 63.1 - 84.3) and 62.8% (90% CI 49.4 - 73.5), respectively. Conclusions: Although the study is still ongoing, adjuvant sunitinib and VPA were considered to be safe and tolerable treatments for high-risk uveal melanoma. Sunitinib showed a tendency for a better outcome, thus a Cohort 2 was created to investigate the safety and potential improvement of 18-month RFS rate with 12 months of treatment with sunitinib. Clinical trial information: NCT02068586.

Download Full-text

Differential expression of HLA-A and B-alleles on uveal melanoma as determined by immuno-histology

Ocular Immunology and Inflammation ◽

10.3109/09273949609069122 ◽

1996 ◽

Vol 4 (1) ◽

pp. 1-14 ◽

Cited By ~ 12

Author(s):

Itte de Waard-siebinga ◽

Jos G. A. Houbiers ◽

Carina G. J. M. Hilders ◽

Didi de Wolff-rouendaal ◽

Martine J. Jager

Keyword(s):

Differential Expression ◽

Uveal Melanoma

Download Full-text

Uveal Melanoma Identified as Ocular Mass on Point-of-care Ultrasound

Clinical Practice and Cases in Emergency Medicine ◽

10.5811/cpcem.2021.4.52115 ◽

2021 ◽

Vol 5 (3) ◽

pp. 367-368

Author(s):

Hannah Spungen ◽

Daniel Weingrow

Keyword(s):

Emergency Department ◽

Retinal Detachment ◽

Uveal Melanoma ◽

Vision Loss ◽

Point Of Care ◽

Black Spot ◽

Distant Metastases ◽

Posterior Chamber ◽

Point Of Care Ultrasound ◽

Point Of Care Ultrasonography

Case Presentation: A 41-year-old man presented to the emergency department with five months of progressive monocular vision loss in his right eye, which he described as a gradually descending and enlarging black spot. He had no light perception in his right eye with elevated intraocular pressure and an afferent pupillary defect, while his left eye visual acuity and pupillary exam was normal. Point-of-care ultrasound demonstrated a hyperechoic, pedunculated mass in the posterior chamber of his right eye, consistent with a diagnosis of ocular melanoma. Ophthalmology scheduled the patient for an elective, right eye enucleation the following week, after which a diagnosis of uveal melanoma (UM) was confirmed on histopathology. Discussion: Uveal melanoma is an uncommon diagnosis that requires prompt intervention and surveillance due to the possibility of distant metastases arising in up to 50% of patients. Emergency department diagnosis of UM may be confounded by features of other intraocular pathology, such as increased ocular pressure or the finding of retinal detachment on fundoscopy. When emergency providers encounter glaucoma or retinal detachment on physical exam, point-of-care ultrasonography represents a key adjunct in the timely diagnosis and referral of this potentially vision- and life-threatening malignancy.

Download Full-text